New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
05:23 EDTSNY, LLYSanofi, Eli Lilly announce licensing agreement for Cialis OTC
Sanofi (SNY) and Eli Lilly (LLY) announced an agreement to pursue regulatory approval of nonprescription Cialis -tadalafil. Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction. Under the terms of the agreement, Sanofi acquires the exclusive rights to apply for approval of Cialis OTC in the United States, Europe, Canada and Australia. Sanofi also holds exclusive rights to market Cialis OTC following Sanofi's receipt of all necessary regulatory approvals. If approved, Sanofi anticipates providing Cialis OTC after expiration of certain patents. Terms of the licensing agreement were not disclosed.
News For SNY;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2014
10:00 EDTLLYZimmer antitrust probe extended, Lilly/Novartis deal cleared by EU, Reuters says
Subscribe for More Information
08:35 EDTLLYEli Lilly to discontinue Tabalumab development based on Phase 3 lupus results
Eli Lilly will discontinue development of tabalumab­, being studied for the treatment of systemic lupus erythematosus, commonly known as lupus, due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns. The decision to discontinue development of tabalumab for lupus is expected to result in a Q3 charge to research and development expense of up to $75M pretax, or approximately 4c-5c per share after-tax.
September 30, 2014
16:39 EDTSNY, LLYCMS discloses drug makers' payments to doctors, WSJ says
Subscribe for More Information
10:53 EDTSNYRegeneron dupilumab opportunity improved with new data, says Piper Jaffray
Piper Jaffray said it is increasingly optimistic about dupilumab's broad potential in allergic diseases following the Phase II data on chronic sinusitis with nasal polyps as well as prior data in atopic dermatitis and asthma. The firm views dupilumab as a potential blockbuster and reiterates its Overweight rating and $382 price target on Regeneron (REGN), which announced the data in partnership with Sanofi (SNY).
07:30 EDTSNY, LLYSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
05:16 EDTSNYRegeneron, Sanofi announce positive Phase 2 top-line dupilumab results
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps, or CSwNP, who did not respond to intranasal corticosteroids. In the study, dupilumab resulted in a statistically-significant improvement in the size of nasal polyps, as measured by endoscopic Nasal Polyp Score, the primary endpoint of the study. Statistically significant improvements in all secondary efficacy endpoints were also observed, including objective measures of sinusitis by CT scan, nasal air flow, and patient-reported symptoms. In a pre-specified exploratory analysis, dupilumab-treated patients who also had asthma demonstrated significant improvements in asthma control. The safety profile was consistent with previous studies. The most common AEs with dupilumab were injection site reactions, nasopharyngitis, oropharyngeal pain, epistaxis, headache and dizziness.
September 24, 2014
17:01 EDTSNYMannKind announces closing of global licensing agreement with Sanofi
Subscribe for More Information
08:10 EDTSNYSanofi unit announces research collaboration
Subscribe for More Information
September 23, 2014
09:00 EDTLLY, SNYBofa/Merill special situations team to hold an analyst/industry conference call
Subscribe for More Information
September 22, 2014
07:21 EDTLLY, SNYEBD Group to hold a conference
Subscribe for More Information
September 18, 2014
15:57 EDTLLYFDA approves Trulicity with boxed warning, post-marketing study requirements
Subscribe for More Information
15:55 EDTLLYFDA approves Eli Lilly type 2 diabetes drug
Subscribe for More Information
11:15 EDTLLYRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
08:12 EDTLLYEli Lilly's Cyramza for gastric cancer shows positive Phase 3 results
Eli Lilly announced results of the global Phase III trial of ramucirumab - CYRAMZA - in combination with paclitaxel in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma. The addition of ramucirumab to paclitaxel showed a statistically significant improvement in median overall survival, meeting its primary endpoint; it also met secondary endpoints of progression-free survival and objective response rate. Data from the trial were first presented in January. Ramucirumab has now been the focus of two positive Phase III gastric cancer trials that have demonstrated statistically significant improvements in both overall survival and progression-free survival.
08:01 EDTLLYDow AgroSciences announces R&D agreement with Lilly's Elanco
Two Indiana agricultural companies, Elanco, the animal health division of Eli Lilly and Company (LLY), and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (DOW), are announcing a strategic research and development agreement that will focus on developing integrated solutions to enable livestock producers to increase meat and milk production to meet the demands of the growing global population.
06:10 EDTLLYFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use